Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award
-- First-ever award honors high-achieving alumni of U.K. universities
LAKE FOREST, Illinois, July 7, 2015 /PRNewswire/ -- Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing on developing orphan oncology compounds, announced that its co-founder and CEO, Chandler D. Robinson MD, MBA, MSc, received the British Council's Education U.K. Alumni Entrepreneurial Award. The British Council selected one recipient from each of China, India, and the United States. The award recognizes outstanding achievements made by entrepreneurs who have leveraged their U.K. education in their subsequent successes. Dr. Robinson was selected due to his entrepreneurial activities which he burnished while he was a Gates Scholar at the University of Cambridge.
"The applicants who stood out among the pack were the alumni who clearly demonstrated how their U.K. education prepared them for competitive and demanding careers," said Dr. Gretchen Dobson, chair of the U.S. judging panel.
As a recipient of the award, the British Council will be hosting Dr. Robinson's upcoming trip to London this July 13th through the 18th. As part of the trip, Dr. Robinson is scheduled to go to 10 Downing Street on July 15th. The British Council is also arranging for meetings between Dr. Robinson and biotechnology industry leaders.
Dr. Robinson said, "The U.K. gave me a global and diverse perspective, which is helping Monopar achieve results beyond the United States. As example, Monopar anticipates very shortly to announce a partnering agreement with an EU entity that is globally recognized as a leader in biotechnology drug development. This partner will be responsible for moving forward Monopar's HuATN-658 proprietary antibody into clinical trials in cancer patients with advanced solid tumors."
About Monopar Therapeutics
Monopar Therapeutics' mission is to develop life-altering orphan oncology therapeutics. Dr. Robinson co-founded Monopar in 2014 as a privately-held company, and is in the process of raising funds to acquire and develop therapeutic compounds for the potential treatment of severe, refractory cancers. Monopar plans to be announcing its first collaboration within the next few weeks. For more information about Monopar Therapeutics, visit http://monopartherapeutics.com.
About the British Council
The British Council is the UK's international organisation for cultural relations and educational opportunities. We create international opportunities for the people of the UK and other countries and build trust between them worldwide.
We work in more than 100 countries and our 8,000 staff – including 2,000 teachers – work with thousands of professionals and policy makers and millions of young people every year by teaching English, sharing the arts and delivering education and society programmes.
We are a UK charity governed by Royal Charter. A core publicly-funded grant provides less than 20 per cent of our turnover which last year was £864 million. The rest of our revenues are earned from services which customers around the world pay for, through education and development contracts and from partnerships with public and private organisations. All our work is in pursuit of our charitable purpose and supports prosperity and security for the UK and globally.
For more information, please visit: www.britishcouncil.org. You can also keep in touch with the British Council through http://twitter.com/britishcouncil and http://blog.britishcouncil.org/.
For more information about the Alumni Awards, please visit Education UK Alumni Awards.
Investor Contact:
Monopar Therapeutics
Chandler D. Robinson, MD, MBA, MSc
robinson@monopartherapeutics.com
Media Contact:
Janine McCargo
Tiberend Strategic Advisors, Inc. (US)
646 605 5150
jmccargo@tiberend.com
Share this article